Information on this site is for research purposes only.

Close Icon

Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma.

Journal of Investivative Dermatology {focus_keyword} Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma. Journal of Investivative DermatologyJ Invest Dermatol. 2004 Mar;122(3):594-601.

Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma.

Nagai M1, Hasegawa M, Takehara K, Sato S.

1Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Abstract

Abnormal production of reactive oxygen species (ROS) induces tissue damage and superoxide dismutase (SOD) that converts superoxide radicals to hydrogen peroxide functions as defense against ROS. Cu/Zn SOD administration has been shown to be effective for various fibrotic conditions by inhibiting the fibrogenic effects of ROS. We hypothesized that autoimmune background in localized scleroderma induced anti-Cu/Zn SOD autoantibodies that inhibited SOD activity and thereby contributed to fibrosis by increasing ROS. ELISA using human purified Cu/Zn SOD revealed that IgG or IgM anti-Cu/Zn SOD Ab was detected in the serum of 89% of localized scleroderma patients, especially 100% of patients with generalized morphea, the severest form of localized scleroderma, but was positive only in the serum of less than 15% of patients with other autoimmune disorders, including systemic sclerosis, systemic lupus erythematosus, dermatomyositis, and autoimmune bullous disorders. The immunoblotting analysis confirmed the presence of IgG anti-Cu/Zn SOD Ab in sera from localized scleroderma patients. Remarkably, anti-Cu/Zn SOD autoantibody could inhibit Cu/Zn SOD enzymatic activity. Collectively, these results indicate that anti-Cu/Zn SOD Ab is a novel, major autoantibody in localized scleroderma, and also suggest that the autoantibody may play a role in the development of fibrosis by directly inhibiting SOD activity.

Visit Us On TwitterVisit Us On FacebookVisit Us On Google PlusVisit Us On YoutubeCheck Our Feed